Biogen Inc vs Dolby Laboratories, Inc. — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Dolby Laboratories, Inc. trades at $60.91 (market cap $5.75B). The key difference: Biogen Inc is far larger — about 5.2× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DLB | |
|---|---|---|
Market Cap | $30.13B | $5.75B |
Sector | Health | Industrials |
52-Week High | $216.63 | $75.62 |
52-Week Low | $128.93 | $48.51 |
Enterprise Value | $37.20B | $5.12B |
Dividend Yield | — | 2.35% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →